These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 30826768)

  • 1. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.
    Nishimura R; Kato H; Kisanuki K; Oh A; Hiroi S; Onishi Y; Guelfucci F; Shimasaki Y
    BMJ Open; 2019 Mar; 9(3):e025806. PubMed ID: 30826768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of persistence and adherence between fixed-dose combinations and two-pill combinations in Japanese patients with type 2 diabetes.
    Nishimura R; Kato H; Kisanuki K; Oh A; Onishi Y; Guelfucci F; Shimasaki Y
    Curr Med Res Opin; 2019 May; 35(5):869-878. PubMed ID: 30460858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of persistence and adherence between DPP-4 inhibitor administration frequencies in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.
    Oh A; Kisanuki K; Nishigaki N; Shimasaki Y; Sakaguchi K; Morimoto T
    Curr Med Res Opin; 2020 Mar; 36(3):387-395. PubMed ID: 31778076
    [No Abstract]   [Full Text] [Related]  

  • 4. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns in hyperlipidaemia patients based on administrative claim databases in Japan.
    Wake M; Onishi Y; Guelfucci F; Oh A; Hiroi S; Shimasaki Y; Teramoto T
    Atherosclerosis; 2018 May; 272():145-152. PubMed ID: 29604481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
    Gor D; Lee TA; Schumock GT; Walton SM; Gerber BS; Nutescu EA; Touchette DR
    J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents in Japanese patients with type 2 diabetes mellitus: a claims database analysis.
    Nishimura R; Takeshima T; Iwasaki K; Aoi S
    BMJ Open; 2022 Mar; 12(3):e045966. PubMed ID: 35277396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan.
    Wake M; Oh A; Onishi Y; Guelfucci F; Shimasaki Y; Teramoto T
    Atherosclerosis; 2019 Mar; 282():19-28. PubMed ID: 30669019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to dipeptidyl peptidase-4 inhibitor therapy among type 2 diabetes patients with employer-sponsored health insurance in Japan.
    Kurtyka K; Nishikino R; Ito C; Brodovicz K; Chen Y; Tunceli K
    J Diabetes Investig; 2016 Sep; 7(5):737-43. PubMed ID: 27182033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting.
    Lv L; Brady BL; Xie L; Guevarra M; Turchin A
    Prim Care Diabetes; 2024 Oct; 18(5):511-517. PubMed ID: 38991896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND).
    Tajima A; Tobe K; Eiki JI; Origasa H; Watada H; Shimomura I; Tokita S; Kadowaki T
    BMJ Open Diabetes Res Care; 2022 Dec; 10(6):. PubMed ID: 36585033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis.
    Kadowaki T; Sarai N; Hirakawa T; Taki K; Iwasaki K; Urushihara H
    Diabetes Obes Metab; 2018 Dec; 20(12):2830-2839. PubMed ID: 29974673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims data.
    Miwa T; Yoshida S; Nakajima A; Koto R; Nishimura R
    Diabetol Int; 2024 Jul; 15(3):483-494. PubMed ID: 39101196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
    Cooke CE; Lee HY; Tong YP; Haines ST
    Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42).
    Fujihara K; Igarashi R; Matsunaga S; Matsubayashi Y; Yamada T; Yokoyama H; Tanaka S; Shimano H; Maegawa H; Yamazaki K; Kawai K; Sone H
    Medicine (Baltimore); 2017 Feb; 96(7):e6122. PubMed ID: 28207538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
    Cai J; Divino V; Burudpakdee C
    Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes Mellitus in Japan from 2012-2020: a Time-Series Analysis.
    Iketani R; Imai S
    Biol Pharm Bull; 2023; 46(4):592-598. PubMed ID: 37005303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study.
    Zerovnik S; Kos M; Locatelli I
    BMJ Open; 2021 Sep; 11(9):e051549. PubMed ID: 34518273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.